SurmodicsSRDX
SRDX
0
Funds holding %
of 7,398 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
117% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 12
100% more funds holding in top 10
Funds holding in top 10: 1 [Q3] → 2 (+1) [Q4]
95% more call options, than puts
Call options by funds: $1.33M | Put options by funds: $681K
10% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 40
10% more funds holding
Funds holding: 126 [Q3] → 138 (+12) [Q4]
4% more capital invested
Capital invested by funds: $459M [Q3] → $476M (+$17.6M) [Q4]
0.79% more ownership
Funds ownership: 83.47% [Q3] → 84.26% (+0.79%) [Q4]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$43
39%
upside
Avg. target
$43
39%
upside
High target
$43
39%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
Lake Street Brooks O'Neil 27% 1-year accuracy 4 / 15 met price target | 39%upside $43 | Buy Upgraded | 7 Mar 2025 |
Financial journalist opinion
Based on 4 articles about SRDX published over the past 30 days
Positive
Zacks Investment Research
2 weeks ago
Here's Why You Should Retain Surmodics Stock in Your Portfolio Now
SRDX stock falls more than 26% so far this year. However, this provides a unique opportunity to generate double-digit returns within a couple of months.
Negative
Zacks Investment Research
3 weeks ago
SRDX Stock Falls Following Plan for Legal Action Against FTC Challenge
The FTC has blocked GTCR's $627M acquisition of SRDX, citing anti-competitive concerns. Surmodics has responded to the challenge and plans to fight the decision in court.
Neutral
Business Wire
3 weeks ago
Surmodics Issues Statement on U.S. Federal Trade Commission Challenge to Proposed Acquisition of Surmodics by Funds Affiliated with GTCR
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a provider of medical device and in vitro diagnostic technologies to the healthcare industry, today provided the following statement in response to the U.S. Federal Trade Commission's (“FTC” or the “Agency”) announcement that it will challenge the proposed acquisition of Surmodics (the “Merger”) by funds affiliated with GTCR LLC (“GTCR”), which have an equity investment in Biocoat Inc., a maker of medical coatings: “Surmodics.
Negative
Reuters
3 weeks ago
FTC sues to block private equity firm's deal to buy medical device coatings maker Surmodics
The U.S. Federal Trade Commission sued on Thursday to block medical device coatings maker Surmodics' acquisition by private equity firm GTCR, with the regulatory agency alleging the deal was anticompetitive.
Positive
Benzinga
1 month ago
Top 3 Health Care Stocks You'll Regret Missing This Month
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Positive
Zacks Investment Research
1 month ago
SurModics (SRDX) Loses -13.87% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for SurModics (SRDX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Neutral
Business Wire
1 month ago
Surmodics Announces Successful Early Clinical Use of Pounce™ XL Thrombectomy System, Suitable for Non-Surgical Removal of Thrombi and Emboli from Iliac and Femoral Arteries
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced the successful early clinical use of its Pounce™ XL Thrombectomy System. The Pounce XL Thrombectomy System received U.S. Food and Drug Administration (FDA) 510(k) clearance in September 2024, and is currently in limited market release (LMR), with full commercial launch planned following completion of the LMR.
Negative
Zacks Investment Research
1 month ago
Surmodics Stock Down Despite Q1 Earnings Beat, Gross Margin Up
Despite the strength in Pounce thrombectomy device platforms, SRDX's first-quarter fiscal 2025 top line is dampened by weak segmental revenues.
Positive
Zacks Investment Research
2 months ago
Compared to Estimates, SurModics (SRDX) Q1 Earnings: A Look at Key Metrics
The headline numbers for SurModics (SRDX) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Negative
Zacks Investment Research
2 months ago
SurModics (SRDX) Reports Q1 Loss, Misses Revenue Estimates
SurModics (SRDX) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to break-even earnings per share a year ago.
Charts implemented using Lightweight Charts™